SelectQuote Q1 FY2027: Revenue Drops 15%, Loss Narrows, But Core Challenges Persist

What happened

SelectQuote reported Q1 FY2027 revenue of $280.0 million, down 14.8% from $328.8 million a year earlier, while net loss improved to $20.3 million from $30.5 million, reflecting continued cost discipline but weaker top-line demand. The revenue decline aligns with prior signals of softening Medicare Advantage submissions and pharmacy reimbursement pressure, as highlighted in the Q3 FY2026 report. Despite the narrower loss, the company still generated negative net income, and the release does not address the key concerns around operating cash flow quality or working-capital timing benefits that were critical to the prior WAIT rating. The quarter's results suggest that the partner-driven headwinds were not fully offset by the Senior segment's profitability or SelectRx member growth, which had been expected to drive improvement. Management's commentary on Adjusted EBITDA, though partially truncated, likely shows a modest level but the sustainability of cash conversion remains unproven.

Implication

The Q1 FY2027 results do not resolve the key uncertainties that underpinned the WAIT rating. The top-line contraction indicates that carrier incentives and pharmacy economics remain under pressure, which could further impair commission receivables and cash generation. While the narrowing loss is a positive step, it may be driven by cost cuts rather than fundamental improvement, and the absence of operating cash flow data in the release keeps the issue of working-capital normalization open. The NYSE compliance status is still not addressed, and although the cure period may have ended, the lack of confirmation adds uncertainty. Until the company demonstrates sustained positive operating cash flow without one-time benefits and clears listing concerns, the risk/reward remains unattractive.

Thesis delta

The thesis is modestly weakened by the Q1 FY2027 revenue decline, which suggests that the company's growth engine is stalling at a time when cash flow quality was already a concern. The probability of the bear case, which assumed working-capital reversal and cash flow below $10M, has increased, while the bull case of Healthcare Services EBITDA above $10M appears less likely given the top-line softness. The WAIT rating remains appropriate, but the entry points for re-engagement have likely shifted lower, and we would require concrete evidence of operating cash flow durability before considering any upgrade.